Customize
Quick Links

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Incyte Corporation and Celgene Corporation.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

LIVE Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis

LIVE Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis


February 21, 2019
8:00 PM EST

Activity Overview

Virtual Tumor Board®: Advancing Polycythemia Vera and Myelofibrosis will explore current trends in the prognostic scoring, molecular diagnostic studies, and appropriate guideline-based management of myeloproliferative neoplasms (MPNs), as well as current and emerging therapeutic strategies across MPNs. By applying evidence in real-world case scenarios, this program contextualizes that evidence to ensure that practitioners are up-to-date with recent developments in molecular diagnostics, the effect of diagnostic techniques on therapeutic decision-making, current clinical trial findings, evolving treatment paradigms, and the mechanistic rationale for novel therapeutic approaches in the context of MPN pathophysiology.

Benefits of Attending

  • Improve familiarity with molecular diagnostics and their impact on clinical decision-making in myelofibrosis (MF) and polycythemia vera (PV)
  • Gain expert insights into the mechanistic characteristics of treatments for MF and PV and how these mechanisms relate to the underlying pathophysiology of myeloproliferative neoplasms (MPNs)
  • Develop a deeper understanding of clinical data with existing and emerging agents in PV and MF management and evidence-based treatment strategies in specific clinical situations across MPNs
  • Exposure to best practices for multidisciplinary management of MPNs, including the role of nurses in recruiting patients for clinical trials, counseling patients, and working with physicians

Acknowledgment of Commercial Support

This activity is supported by educational grants from Incyte and Celgene Corporation.

Target Audience

This educational activity is directed toward hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with MPNs. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of MPNs may also participate.

Learning Objectives

After participating in this activity, you should be better prepared to:

  • Discuss recent developments in molecular diagnostics and its impact on therapeutic decision-making in the management of myelofibrosis (MF) and polycythemia vera (PV)
  • Describe the mechanistic rationale for overlap of MF and PV therapeutic approaches in the context of the current treatment landscape
  • Evaluate clinical trial data on emerging agents and regimens to treat MF and PV
  • Integrate recent trial findings to optimize clinical decision-making and care for patients with MF and PV

Chair

Ronald Hoffman, MDRonald Hoffman, MD
Albert A. and Vera G. List Professor of Medicine
Director, Myeloproliferative Neoplasm Program
Tisch Cancer Institute
Icahn School of Medicine
Mount Sinai School of Medicine
New York, NY







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
2425262728
Filter By